Apogee Therapeutics, Inc. Research and Development Expense
Apogee Therapeutics, Inc. (APGE) reported Research and Development Expense of $67.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Apogee Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $67.30M, a 20.82% increase year-over-year.
- Apogee Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $60.82M, a 31.11% increase year-over-year.
- Apogee Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $58.44M, a 2.96% decline year-over-year.
- Apogee Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $54.18M, a 18.52% increase year-over-year.
- Apogee Therapeutics, Inc. research and development expense for fiscal 2025 was $214.71M, a 27.91% increase from fiscal 2024.
- Apogee Therapeutics, Inc. research and development expense for fiscal 2024 was $167.87M, a 145.33% increase from fiscal 2023.
- Apogee Therapeutics, Inc. research and development expense for fiscal 2023 was $68.42M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 5 month | Research and Development Expense 6 month | Research and Development Expense 8 month | Research and Development Expense 9 month | Research and Development Expense 11 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $67.30M 10-Q · filed 2026-08-10 | $128.12M 10-Q · filed 2026-08-10 | $186.56M derived: sum of 3 quarters · filed 2026-08-10 | $240.74M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $60.82M 10-Q · filed 2026-05-11 | $119.26M derived: sum of 2 quarters · filed 2026-05-11 | $173.44M derived: sum of 3 quarters · filed 2026-05-11 | $229.14M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | $58.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $112.62M derived: sum of 2 quarters · filed 2026-03-02 | $168.32M derived: sum of 3 quarters · filed 2026-08-10 | $214.71M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $54.18M 10-Q · filed 2025-11-10 | $109.88M derived: sum of 2 quarters · filed 2026-08-10 | $156.27M 10-Q · filed 2025-11-10 | $216.50M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $55.70M 10-Q · filed 2026-08-10 | $102.09M 10-Q · filed 2026-08-10 | $162.32M derived: sum of 3 quarters · filed 2026-08-10 | $208.03M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $46.39M 10-Q · filed 2026-05-11 | $106.62M derived: sum of 2 quarters · filed 2026-05-11 | $152.33M derived: sum of 3 quarters · filed 2026-05-11 | $185.54M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | $60.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $105.94M derived: sum of 2 quarters · filed 2026-03-02 | $139.15M derived: sum of 3 quarters · filed 2026-03-02 | $167.87M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $45.71M 10-Q · filed 2025-11-10 | $78.92M derived: sum of 2 quarters · filed 2025-11-10 | $107.64M 10-Q · filed 2025-11-10 | $136.59M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | $33.21M 10-Q · filed 2025-08-11 | $61.92M 10-Q · filed 2025-08-11 | $90.88M derived: sum of 3 quarters · filed 2026-03-02 | $107.94M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $28.72M 10-Q · filed 2025-05-12 | $57.67M derived: sum of 2 quarters · filed 2026-03-02 | $74.74M derived: sum of 3 quarters · filed 2026-03-02 | $88.69M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $28.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $46.02M derived: sum of 2 quarters · filed 2026-03-02 | $59.97M derived: sum of 3 quarters · filed 2026-03-02 | $68.42M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $17.07M 10-Q · filed 2024-11-12 | $31.02M derived: sum of 2 quarters · filed 2024-11-12 | $39.47M 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | $13.95M 10-Q · filed 2024-08-12 | $22.40M 10-Q · filed 2024-08-12 | |||||
| 2023-03-31 | $8.46M 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | $27.79M 10-K · filed 2024-03-05 | ||||||
| 2022-09-30 | $9.88M 10-Q · filed 2023-11-13 | $11.33M derived: sum of 2 quarters · filed 2023-11-13 | $15.58M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $1.45M 10-Q · filed 2023-08-28 | $5.69M 10-Q · filed 2023-08-28 |